Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · N12159/S129

SURGICELTM POWDER Absorbable Hemostatic Powder

ETHICON, Inc. · Decision date Jul 28, 2026

FDA DECISIONN12159/S129

What did the FDA approve?

FDA records N12159/S129 as a supplement to PMA null, with the supplement type “Normal 180 Day Track”. The recorded decision is approval, dated Jul 28, 2026.

FDA approval order statement

for the use of a New Resin and Mold at Alltrista Plastics, an Ethicon, Inc. External Supplier
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track
Clinical specialty
General, Plastic Surgery
Decision date
Jul 28, 2026
FDA change category
Change Design/Components/Specifications/Material

FDA source record

Regulatory record facts

Identifier
N12159/S129
Regulatory pathway
PMA supplement
Applicant
ETHICON, Inc.
Product code
LMG
Decision code
APPR
Decision date
Jul 28, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Agent, absorbable hemostatic, non-collagen based.

Applicant
ETHICON, Inc.
Product code
LMG
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. N12159/S129 received

    Application receipt date recorded by FDA.

  2. N12159/S129 · FDA decision

    Normal 180 Day Track

Related devices and submissions

Explore the linked device profile

Other records with product code LMG

Product / regulatory recordCompanyPathwayDecision dateSource
Baxter Healthcare CorporationPMA supplementNov 7, 2026FDA
ETHICON, Inc.PMA supplementNov 5, 2026FDA
Baxter Healthcare CorporationPMA supplementAug 7, 2026FDA
Baxter Healthcare CorporationPMA supplementAug 7, 2026FDA
Arista AHP050038/S044
Davol, Inc.PMA supplementJul 15, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

ETHICON, Inc.

Headquarters
Not reported
Brand website
ethicon.com
FDA applicant address
1000 Rte. 202, Raritan, NJ, 08869

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records